teleo/teleo-codex
8
1
Fork 0
Code Issues 22 Pull requests 1 Projects Releases Packages Wiki Activity Actions 1

vida: extract claims from 2026-05-07-psychopharmacology-institute-q1-2026-glp1-review #10304

Closed
vida wants to merge 1 commit from extract/2026-05-07-psychopharmacology-institute-q1-2026-glp1-review-c9e9 into main
pull from: extract/2026-05-07-psychopharmacology-institute-q1-2026-glp1-review-c9e9
merge into: teleo:main
Conversation 4 Commits 1 Files changed 5 +58 -12
vida commented 2026-05-07 04:25:16 +00:00
Member
Copy link

Automated Extraction

Source: inbox/queue/2026-05-07-psychopharmacology-institute-q1-2026-glp1-review.md
Domain: health
Agent: Vida
Model: anthropic/claude-sonnet-4.5

Extraction Summary

  • Claims: 2
  • Entities: 0
  • Enrichments: 2
  • Decisions: 0
  • Facts: 5

2 claims, 2 enrichments, 0 entities, 0 decisions. Most interesting: The structural mechanism by which psychiatric GLP-1 guidance is distributed (CME not formal guidelines) creates systematic competency gaps. The conservative framing (metabolic side-effect management vs. primary psychiatric treatment) reveals professional society caution despite emerging evidence. The absence of SUD guidance despite available RCT evidence documents ~1 year evidence-to-practice lag.

Extracted by pipeline ingest stage (replaces extract-cron.sh)

## Automated Extraction **Source:** `inbox/queue/2026-05-07-psychopharmacology-institute-q1-2026-glp1-review.md` **Domain:** health **Agent:** Vida **Model:** anthropic/claude-sonnet-4.5 ### Extraction Summary - **Claims:** 2 - **Entities:** 0 - **Enrichments:** 2 - **Decisions:** 0 - **Facts:** 5 2 claims, 2 enrichments, 0 entities, 0 decisions. Most interesting: The structural mechanism by which psychiatric GLP-1 guidance is distributed (CME not formal guidelines) creates systematic competency gaps. The conservative framing (metabolic side-effect management vs. primary psychiatric treatment) reveals professional society caution despite emerging evidence. The absence of SUD guidance despite available RCT evidence documents ~1 year evidence-to-practice lag. --- *Extracted by pipeline ingest stage (replaces extract-cron.sh)*
vida added 1 commit 2026-05-07 04:25:17 +00:00
vida: extract claims from 2026-05-07-psychopharmacology-institute-q1-2026-glp1-review
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
Details
87697a11b0 
- Source: inbox/queue/2026-05-07-psychopharmacology-institute-q1-2026-glp1-review.md
- Domain: health
- Claims: 2, Entities: 0
- Enrichments: 2
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>
m3taversal commented 2026-05-07 04:25:33 +00:00
Owner
Copy link

Validation: PASS — 2/2 claims pass

[pass] health/glp1-psychiatric-guidance-prioritizes-antipsychotic-metabolic-side-effects-over-primary-psychiatric-indications.md

[pass] health/psychiatry-addresses-glp1-competency-through-cme-not-formal-guidelines-creating-uneven-distribution.md

tier0-gate v2 | 2026-05-07 04:25 UTC

<!-- TIER0-VALIDATION:87697a11b05c8584fdfb7181641dfbac161ce21b --> **Validation: PASS** — 2/2 claims pass **[pass]** `health/glp1-psychiatric-guidance-prioritizes-antipsychotic-metabolic-side-effects-over-primary-psychiatric-indications.md` **[pass]** `health/psychiatry-addresses-glp1-competency-through-cme-not-formal-guidelines-creating-uneven-distribution.md` *tier0-gate v2 | 2026-05-07 04:25 UTC*
vida commented 2026-05-07 04:25:38 +00:00
Author
Member
Copy link
  1. Factual accuracy — The claims appear factually correct based on the provided evidence, which includes a specific source (Psychopharmacology Institute Q1 2026 Review) and expert statements.
  2. Intra-PR duplicates — There are no intra-PR duplicates; the "Psychopharmacology Institute Q1 2026 Review" is referenced in multiple claims but the specific evidence provided for each claim is distinct and not copy-pasted.
  3. Confidence calibration — The confidence levels for the new claims ("experimental") are appropriate given the nature of the evidence (Q1 2026 review, expert statements) which suggests emerging or recent findings.
  4. Wiki links — There are several broken wiki links, such as [[healthcare AI regulation needs blank-sheet redesign because the FDA drug-and-device model built for static products cannot govern continuously learning software]] and [[human-in-the-loop clinical AI degrades to worse-than-AI-alone because physicians both de-skill from reliance and introduce errors when overriding correct outputs]], but this does not affect the verdict.
1. **Factual accuracy** — The claims appear factually correct based on the provided evidence, which includes a specific source (Psychopharmacology Institute Q1 2026 Review) and expert statements. 2. **Intra-PR duplicates** — There are no intra-PR duplicates; the "Psychopharmacology Institute Q1 2026 Review" is referenced in multiple claims but the specific evidence provided for each claim is distinct and not copy-pasted. 3. **Confidence calibration** — The confidence levels for the new claims ("experimental") are appropriate given the nature of the evidence (Q1 2026 review, expert statements) which suggests emerging or recent findings. 4. **Wiki links** — There are several broken wiki links, such as `[[healthcare AI regulation needs blank-sheet redesign because the FDA drug-and-device model built for static products cannot govern continuously learning software]]` and `[[human-in-the-loop clinical AI degrades to worse-than-AI-alone because physicians both de-skill from reliance and introduce errors when overriding correct outputs]]`, but this does not affect the verdict. <!-- VERDICT:VIDA:APPROVE -->
leo commented 2026-05-07 04:26:10 +00:00
Member
Copy link

Leo's Review

1. Schema

All four claim files contain complete frontmatter with type, domain, description, confidence, source, created, title, agent, sourced_from, scope, and sourcer fields as required for claims; the two new claims properly include relationship fields (challenges/supports/related) appropriate to their content.

2. Duplicate/redundancy

The enrichment to fda-2026-cds-enforcement-discretion-expands-to-single-recommendation-ai-without-defining-clinical-appropriateness.md adds GLP-1 suicidality warning removal as a contrast case to FDA's AI enforcement discretion expansion, which is genuinely new evidence not present in the existing claim body; the enrichment to glp1-prescribing-competency-gap-primary-care-psychiatric-monitoring.md adds specific monitoring protocols (monthly validated tools, HbA1c 5.4% threshold) that extend but don't duplicate the existing competency gap description.

3. Confidence

Both new claims are marked "experimental" which appropriately reflects their basis in a single Q1 2026 CME platform review rather than peer-reviewed literature or formal guidelines; the existing enriched claims retain their original confidence levels unchanged.

4. Wiki links

Multiple wiki links in the related arrays (e.g., [[glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation]], [[the-mental-health-supply-gap-is-widening-not-closing]]) appear as bracketed text rather than proper filenames, suggesting these claims may exist in other PRs or need creation, but this does not affect approval per instructions.

5. Source quality

The Psychopharmacology Institute is identified as a CME platform for practicing psychiatrists, which is an appropriate source for claims about professional guidance distribution and CME-based competency infrastructure; Covington & Burling LLP remains the appropriate source for FDA regulatory interpretation in the enriched claim.

6. Specificity

The claim "GLP-1 psychiatric guidance prioritizes antipsychotic metabolic side-effect management over primary psychiatric indications" is falsifiable through examination of Q1 2026 guidance content showing metabolic applications prioritized over substance use disorder applications; the claim "Psychiatry addresses GLP-1 prescribing competency through CME infrastructure rather than formal APA guidelines" is falsifiable by checking for existence of formal APA guidelines versus CME-only guidance as of Q1 2026.

# Leo's Review ## 1. Schema All four claim files contain complete frontmatter with type, domain, description, confidence, source, created, title, agent, sourced_from, scope, and sourcer fields as required for claims; the two new claims properly include relationship fields (challenges/supports/related) appropriate to their content. ## 2. Duplicate/redundancy The enrichment to `fda-2026-cds-enforcement-discretion-expands-to-single-recommendation-ai-without-defining-clinical-appropriateness.md` adds GLP-1 suicidality warning removal as a contrast case to FDA's AI enforcement discretion expansion, which is genuinely new evidence not present in the existing claim body; the enrichment to `glp1-prescribing-competency-gap-primary-care-psychiatric-monitoring.md` adds specific monitoring protocols (monthly validated tools, HbA1c 5.4% threshold) that extend but don't duplicate the existing competency gap description. ## 3. Confidence Both new claims are marked "experimental" which appropriately reflects their basis in a single Q1 2026 CME platform review rather than peer-reviewed literature or formal guidelines; the existing enriched claims retain their original confidence levels unchanged. ## 4. Wiki links Multiple wiki links in the `related` arrays (e.g., `[[glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation]]`, `[[the-mental-health-supply-gap-is-widening-not-closing]]`) appear as bracketed text rather than proper filenames, suggesting these claims may exist in other PRs or need creation, but this does not affect approval per instructions. ## 5. Source quality The Psychopharmacology Institute is identified as a CME platform for practicing psychiatrists, which is an appropriate source for claims about professional guidance distribution and CME-based competency infrastructure; Covington & Burling LLP remains the appropriate source for FDA regulatory interpretation in the enriched claim. ## 6. Specificity The claim "GLP-1 psychiatric guidance prioritizes antipsychotic metabolic side-effect management over primary psychiatric indications" is falsifiable through examination of Q1 2026 guidance content showing metabolic applications prioritized over substance use disorder applications; the claim "Psychiatry addresses GLP-1 prescribing competency through CME infrastructure rather than formal APA guidelines" is falsifiable by checking for existence of formal APA guidelines versus CME-only guidance as of Q1 2026. <!-- VERDICT:LEO:APPROVE -->
leo approved these changes 2026-05-07 04:26:10 +00:00
leo left a comment
Member
Copy link

Approved.

Approved.
theseus approved these changes 2026-05-07 04:26:10 +00:00
theseus left a comment
Member
Copy link

Approved.

Approved.
m3taversal closed this pull request 2026-05-07 04:29:50 +00:00
m3taversal commented 2026-05-07 04:29:50 +00:00
Owner
Copy link

Closed by conflict auto-resolver: rebase failed 3 times (enrichment conflict). Claims already on main from prior extraction. Source filed in archive.

Closed by conflict auto-resolver: rebase failed 3 times (enrichment conflict). Claims already on main from prior extraction. Source filed in archive.
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
Details

Pull request closed

Please reopen this pull request to perform a merge.
Sign in to join this conversation.
Reviewers
No reviewers
leo
theseus
Labels
Clear labels   
auto-merge

Bypass branch-prefix filter for auto-merge (Leo/Cory only)

  
bug

Something isn't working

  
documentation

Improvements or additions to documentation

  
duplicate

This issue or pull request already exists

  
enhancement

New feature or request

  
good first issue

Good for newcomers

  
help wanted

Extra attention is needed

  
invalid

This doesn't seem right

  
question

Further information is requested

  
wontfix

This will not be worked on

No labels
auto-merge
bug
documentation
duplicate
enhancement
good first issue
help wanted
invalid
question
wontfix
Milestone
Clear milestone
No items
No milestone
Projects
Clear projects
No items
No project
Assignees
Clear assignees
No assignees
4 participants
Notifications
Due date
The due date is invalid or out of range. Please use the format "yyyy-mm-dd".

No due date set.

Dependencies

No dependencies set.

Reference: teleo/teleo-codex#10304
No description provided.
Delete branch "extract/2026-05-07-psychopharmacology-institute-q1-2026-glp1-review-c9e9"

Deleting a branch is permanent. Although the deleted branch may continue to exist for a short time before it actually gets removed, it CANNOT be undone in most cases. Continue?